Femasys Inc. (NASDAQ:FEMY) Financings
Financings
| Raise | Date |
|---|---|
| Private placement of common stock and pre-funded warrants with accompanying warrants Closed: US$30M raised · US$3.2 a share · Warrants at US$2.95 for 36 months · Laidlaw & Company (UK) Ltd. +1 Dealers: Laidlaw & Company (UK) Ltd. (lead), Lake Street Capital Markets, LLC Buyers: Nantahala Capital (Led the financing as new institutional investor); Rosalind Advisors, Inc. Insiders: Members of Femasys' management team participated. Use of proceeds: Support strategic priorities: executing commercial initiatives, advancing clinical programs and key operational objectives | Aug 14, 2026 |
| Public offering of financing Closed: US$8M raised · US$0.36 a share · Warrants at US$0.36 for 60 months · Jones +1 Dealers: Jones (co-lead), Laidlaw & Company (UK) Ltd. (co-lead) Buyers: Jorey Chernett Insiders: Certain officers bought 87,363 shares and accompanying warrants at $0.5151 per share and accompanying warrant Use of proceeds: To accelerate commercialization efforts for its FemaSeed and FemBloc fertility and birth control products | Sep 2, 2025 |
| Public offering of common stock Announced: US$0.85 a share · Jones Dealers: Jones (lead) Use of proceeds: Expansion of commercial efforts, product development, general corporate purposes, capital expenditures, working capital and G&A expenses | May 30, 2025 |
| Private placement of common stock Announced: US$0.85 a share · Jones Dealers: Jones (lead) Insiders: Certain directors and officers buy at a price of $1.02 per share Use of proceeds: Expansion of commercial efforts, product development, general corporate purposes, capital expenditures, working capital and G&A expenses | May 30, 2025 |